Breast Cancer: is cancer that forms in the cells of the breasts. After skin cancer, breast cancer is the most common cancer diagnosed in women in the United States.
Personalized medicine driven by genomic-based treatments continues to increase in importance. Representatives from two distinct healthcare entities – a regional reference lab and commun...
DATE: March 5, 2019TIME: 09:00am PST, 12:00pm EST MicroRNA(miRNA) are short non-coding single stranded RNA molecules that regulate gene expression at the post tran...
Recent clinical successes in cancer genome-inspired personalized medicine have been a major breakthrough in drug discovery. However, 98% of the patients have an incomplete therapeutic respons...
Prodrugs are harmless in their native state, as they are not targeted by human enzymes. But they can be converted into highly toxic compounds (the “drug”) by viral or bacterial en...
DATE: December 13 15,2018TIME: 09:00am PST, 12:00pm EST Breast cancers are classified into three main subtypes according to their receptor status: estrogen receptor-positive...
With significant decrease in the cost of sequencing in numerous commercial as well as cancer center–driven initiatives, genomic profiling is increasingly becoming routine across multipl...
The success of immune checkpoint blockade adds a new therapeutic category to the cancer therapy repertoire. Despite efforts made on cancer cell and immune cell interaction, how cancer cells i...
As the most common female malignancy, breast cancer is the most likely reason that a woman will die of cancer around the world. Breast cancer mortality has dropped in the U.S. by 35% since 19...
Although targeted therapies often elicit profound initial patient responses, these effects are transient due to residual disease leading to acquired resistance. How tumors transition between...
Two projects looking at novel approaches to targeting inflammatory breast cancer will be presented. Inflammatory breast cancer (IBC) is a unique, understudied, and most lethal subtype account...
The oncogenic transcription factor c-MYC (MYC) is deregulated, and often overexpressed, in more than 50% of cancers. MYC deregulation is associated with poor prognosis and aggressive disease,...
DATE: October 11, 2018TIME: 8:00AM PDTSimultaneous quantitation of 6 or more biomarkers in intact tissue specimens holds the key to many questions concerning the biological basis o...
Molecular analyses of cancer biology have tended to segregate between a focus on nucleic acids – DNA, RNA and their modifications – and a focus on proteins and protein function. P...
With over 265,000 new cases per year and over 50,000 deaths, breast and ovarian cancers represent a significant health burden in the USA. Prior work has demonstrated that CD4 helper T c...
DATE: October 2, 2018TIME: 9:00AM PDTUnderstanding the role of distinct cellular phenotypes in tissue function, development, and pathogenesis requires tools that can rapidly and co...
Room air conditions are hypothermic, hypocapnic and hyperphysioxic from the cells’ point of view. Yet we stress cells with these uncontrolled conditions routinely. It is no wonder that...
To ensure the immune system’s balance between the recognition of non-self and the prevention of autoimmunity, the activity of immune cells needs to be strictly controlled. During the pr...
DATE: July 19, 2018TIME: 09:00am PDT Pancreatic ductal adenocarcinoma (PDAC) is a deadly disease with a 5 year-survival rate of approximately 6%. Despite recent...
Triple-negative breast cancer (TNBC) has poor prognosis with frequent relapses and deaths using current standard of care treatments. Metabolic reprograming is now recognized as a fundam...
Tumors are often categorized into standard molecular subtypes. However, largescale studies have demonstrated that patient heterogeneity in the regulatory make-up of tumors remain. At the tran...
On March 16, 2018, the Centers for Medicare and Medicaid Services (CMS) finalized a National Coverage Determination (NCD) for the use of Next Generation Sequencing (NGS) for tumor profiling i...
DATE: April 4, 2018TIME: 09:00am PDT, 12:00pm CEST Multiplex is the ability to characterize three or more biomarkers on a single tissue section. The technique enables the combi...
We recently reported that HDAC6 is involved in the regulation of a number of immunosuppressive checkpoint proteins, including the Program Death Receptor Ligand 1 (PD-L1). This protein is one...
Personalized medicine driven by genomic-based treatments continues to increase in importance. Representatives from two distinct healthcare entities – a regional reference lab and commun...
DATE: March 5, 2019TIME: 09:00am PST, 12:00pm EST MicroRNA(miRNA) are short non-coding single stranded RNA molecules that regulate gene expression at the post tran...
Recent clinical successes in cancer genome-inspired personalized medicine have been a major breakthrough in drug discovery. However, 98% of the patients have an incomplete therapeutic respons...
Prodrugs are harmless in their native state, as they are not targeted by human enzymes. But they can be converted into highly toxic compounds (the “drug”) by viral or bacterial en...
DATE: December 13 15,2018TIME: 09:00am PST, 12:00pm EST Breast cancers are classified into three main subtypes according to their receptor status: estrogen receptor-positive...
With significant decrease in the cost of sequencing in numerous commercial as well as cancer center–driven initiatives, genomic profiling is increasingly becoming routine across multipl...
The success of immune checkpoint blockade adds a new therapeutic category to the cancer therapy repertoire. Despite efforts made on cancer cell and immune cell interaction, how cancer cells i...
As the most common female malignancy, breast cancer is the most likely reason that a woman will die of cancer around the world. Breast cancer mortality has dropped in the U.S. by 35% since 19...
Although targeted therapies often elicit profound initial patient responses, these effects are transient due to residual disease leading to acquired resistance. How tumors transition between...
Two projects looking at novel approaches to targeting inflammatory breast cancer will be presented. Inflammatory breast cancer (IBC) is a unique, understudied, and most lethal subtype account...
The oncogenic transcription factor c-MYC (MYC) is deregulated, and often overexpressed, in more than 50% of cancers. MYC deregulation is associated with poor prognosis and aggressive disease,...
DATE: October 11, 2018TIME: 8:00AM PDTSimultaneous quantitation of 6 or more biomarkers in intact tissue specimens holds the key to many questions concerning the biological basis o...
Molecular analyses of cancer biology have tended to segregate between a focus on nucleic acids – DNA, RNA and their modifications – and a focus on proteins and protein function. P...
With over 265,000 new cases per year and over 50,000 deaths, breast and ovarian cancers represent a significant health burden in the USA. Prior work has demonstrated that CD4 helper T c...
DATE: October 2, 2018TIME: 9:00AM PDTUnderstanding the role of distinct cellular phenotypes in tissue function, development, and pathogenesis requires tools that can rapidly and co...
Room air conditions are hypothermic, hypocapnic and hyperphysioxic from the cells’ point of view. Yet we stress cells with these uncontrolled conditions routinely. It is no wonder that...
To ensure the immune system’s balance between the recognition of non-self and the prevention of autoimmunity, the activity of immune cells needs to be strictly controlled. During the pr...
DATE: July 19, 2018TIME: 09:00am PDT Pancreatic ductal adenocarcinoma (PDAC) is a deadly disease with a 5 year-survival rate of approximately 6%. Despite recent...
Triple-negative breast cancer (TNBC) has poor prognosis with frequent relapses and deaths using current standard of care treatments. Metabolic reprograming is now recognized as a fundam...
Tumors are often categorized into standard molecular subtypes. However, largescale studies have demonstrated that patient heterogeneity in the regulatory make-up of tumors remain. At the tran...
On March 16, 2018, the Centers for Medicare and Medicaid Services (CMS) finalized a National Coverage Determination (NCD) for the use of Next Generation Sequencing (NGS) for tumor profiling i...
DATE: April 4, 2018TIME: 09:00am PDT, 12:00pm CEST Multiplex is the ability to characterize three or more biomarkers on a single tissue section. The technique enables the combi...
We recently reported that HDAC6 is involved in the regulation of a number of immunosuppressive checkpoint proteins, including the Program Death Receptor Ligand 1 (PD-L1). This protein is one...
Follow
